ArticleAllergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology2026
One size does not fit all: uncontrolled T2 inflammation on tezepelumab-a case series.
Article in Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTezepelumab is the most recent human monoclonal antibody in the therapeutic arsenal of patients with severe uncontrolled asthma. It neutralizes thymic stromal lymphopoietin (TSLP). Phase 2 and phase 3 studies showed a significant reduction in asthma exacerbations in the severe asthma population, with the greatest effects seen in patients with a type 2 (T2) phenotype. TSLP is in close relation with the epithelium which is believed to be the starting point of the inflammatory cascade. Hence, blocking TSLP is expected to fully control type 2 inflammation and its actors such as interleukin 4 (IL-4), IL-13, IL-5 and eosinophils. This case report describes asthma patient cases with uncontrolled T2 inflammation on tezepelumab and explores the potential evasion mechanisms of TSLP blockage. CASES PRESENTATION: We report four patients who developed symptomatic uncontrolled T2 inflammation following the initiation to tezepelumab. All cases were biologic-experienced and achieved best asthma control with benralizumab. Several hypotheses have been proposed to explain this phenomenon. One possibility is an immune-driven process within the spectrum of eosinophilic granulomatosis with polyangiitis (EGPA). In EGPA, eosinophils act as immunoregulatory cells and have a critical role in promoting the T2 response, which truly sanction the disease as an eosinophilic immune dysfunction disorder. With such process, targeting upstream signals, such as TSLP may prove ineffective in controlling the self-sustained eosinophilic process. Additionally, local airway immunity, even in the absence of EGPA, could influence the suboptimal response to anti-TSLP therapy by exacerbating the in situ T2 response.
conclusionTezepelumab is not the optimal treatment for all asthma patients requiring biologic therapy. A non-epithelial derived source of inflammation might explain the suboptimal response. These cases stress the importance of phenotyping and individualisation of therapy as essential steps of the severe asthma care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.